Treating COVID-19: 32 recommendations from the Infectious Diseases Society of America
| Recommended | Not recommended |
|---|---|
| Dexamethasone for hospitalized critically ill patients Dexamethasone for hospitalized patients with severe but noncritical COVID-19 Tocilizumab for hospitalized adults with progressive severe or critical COVID-19 who have elevated markers of systemic inflammation Sarilumab for patients who would qualify for tocilizumab, if tocilizumab is not available Convalescent plasma for ambulatory patients with mild to moderate COVID-19 at high risk of progressing to severe disease who have no other treatment options, within 8 days of symptom onset Remdesivir for patients with mild to moderate COVID-19 within 7 days of symptom onset at high risk of progressing to severe disease Remdesivir for 5 days rather than 10 days for patients on supplemental oxygen but not on mechanical ventilation or extracorporeal mechanical ventilation Remdesivir for hospitalized patients with severe COVID-19 Baricitinib with corticosteroids for hospitalized adults with severe COVID-19 Baricitinib with remdesivir for hospitalized patients with severe COVID-19 who cannot receive a corticosteroid Tofacitinib for hospitalized adults with severe COVID-19 but not on noninvasive or invasive mechanical ventilation Fluvoxamine (but only in a clinical trial) Nirmatrelvir-ritonavir within 5 days of symptom onset in ambulatory patients with mild to moderate COVID-19 at high risk of progressing to severe disease Molnupiravir within 5 days of symptom onset in ambulatory adults with mild to moderate COVID-19 at high risk of progressing | Hydroxychloroquine Hydroxychloroquine plus azithromycin for hospitalized patients with COVID-19 Hydroxychloroquine for patients exposed to COVID-19 Lopinavir-ritonavir for patients exposed to COVID-19 Lopinavir-ritonavir for ambulatory patients with mild to moderate COVID-19 Lopinavir-ritonavir for hospitalized patients Glucocorticoids for hospitalized patients with mild to moderate COVID-19 without hypoxemia requiring supplemental oxygen Inhaled corticosteroids for ambulatory patients with mild to moderate COVID-19 Convalescent plasma for hospitalized immunocompetent patients Routine use of convalescent plasma for hospitalized immunocompromised patients Remdesivir for those on mechanical ventilation, extracorporeal membrane oxygenation, or both Famotidine for ambulatory patients with mild to moderate COVID-19 Famotidine for hospitalized patients with severe COVID-19 Ivermectin for hospitalized patients Ivermectin for ambulatory patients Colchicine for hospitalized patients Colchicine for ambulatory patients Anakinra for hospitalized patients with severe COVID-19 |
Based on information in reference 1.